{"id":"W4232022766","doi":"10.1016/j.annonc.2021.08.1154","title":"641TiP Phase Ib/II trial of pembrolizumab (pembro) + vibostolimab combination therapy in patients (Pts) with adenocarcinoma metastatic castration-resistant prostate cancer (mCRPC) or treatment-emergent neuroendocrine mCRPC (t-NE): KEYNOTE-365 cohorts G and H","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Foundation Medicine; Pharmacyclics; Genentech; Astellas Pharma; Merck Sharp and Dohme; Eisai; Invitae; Advanced Accelerator Applications; Menarini Silicon Biosystems; Clovis Oncology; Sanofi Genzyme; Sierra Oncology; Taiho Pharmaceutical; Vertex Pharmaceuticals; Boston Scientific Corporation; Daiichi Sankyo Europe; Sanofi; AstraZeneca; Amgen; Pfizer; GlaxoSmithKline","keywords":"Medicine; Docetaxel; Prostate cancer; Pembrolizumab; Oncology; Olaparib; Internal medicine; Enzalutamide; Cancer; Immunotherapy; Androgen receptor","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007653327,0.0009604768,0.0011171,0.0001657752,0.0003155674,0.0009415612,0.000649641,0.0007489477,0.008464312],"category_scores_gemma":[0.0006362109,0.0003507685,0.001236425,0.0002046048,0.0004703072,0.0006342171,0.0003775953,0.003564693,0.002052039],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000747093,"about_ca_system_score_gemma":0.001003361,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001257401,"about_ca_topic_score_gemma":0.003825605,"domain_scores_codex":[0.999818,0.00006699981,0.000006841447,0.00004039868,0.00001647518,0.00005139181],"domain_scores_gemma":[0.999669,0.00003628234,0.00005620344,0.00002636891,0.00002025961,0.0001918534],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8326787,0.01089532,0.005065353,0.0009641087,0.00199859,0.0001728332,0.0001547632,0.001917658,0.02148753,0.0006506048,0.02908259,0.09493198],"study_design_scores_gemma":[0.8324584,0.1333848,0.01740936,0.00009992129,0.001017251,0.0002319024,0.0000792015,0.0009952741,0.001678616,0.0007547034,0.01185578,0.00003491034],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9572204,0.005739502,0.0008668469,0.002977767,0.000757687,0.003195604,0.01521907,0.0003071722,0.01371594],"genre_scores_gemma":[0.9453808,0.004402369,0.003135804,0.003935366,0.000561903,0.00242549,0.02245084,0.00009770883,0.01760966],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008464312,"threshold_uncertainty_score":0.0283159,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07525017458406637,"score_gpt":0.385290777884475,"score_spread":0.3100406033004087,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}